0.6251
price up icon2.64%   0.0161
after-market Handel nachbörslich: .63 0.0049 +0.78%
loading
Schlusskurs vom Vortag:
$0.609
Offen:
$0.617173
24-Stunden-Volumen:
9,961
Relative Volume:
0.21
Marktkapitalisierung:
$3.48M
Einnahmen:
$14.64M
Nettoeinkommen (Verlust:
$-13.74M
KGV:
-0.086
EPS:
-7.27
Netto-Cashflow:
$-5.04M
1W Leistung:
+8.98%
1M Leistung:
+12.83%
6M Leistung:
+0.02%
1J Leistung:
-71.19%
1-Tages-Spanne:
Value
$0.6123
$0.6259
1-Wochen-Bereich:
Value
$0.5755
$0.6259
52-Wochen-Spanne:
Value
$0.3611
$2.4521

Novabay Pharmaceuticals Inc Stock (NBY) Company Profile

Name
Firmenname
Novabay Pharmaceuticals Inc
Name
Telefon
510-899-8800
Name
Adresse
2000 Powell Street, Suite 1150, Emeryville, CA
Name
Mitarbeiter
86
Name
Twitter
@NovaBayPharma
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
NBY's Discussions on Twitter

Vergleichen Sie NBY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NBY
Novabay Pharmaceuticals Inc
0.6251 3.48M 14.64M -13.74M -5.04M -7.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Novabay Pharmaceuticals Inc Stock (NBY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2019-09-18 Eingeleitet Ladenburg Thalmann Buy
2018-07-06 Bestätigt H.C. Wainwright Buy
2017-11-15 Bestätigt Laidlaw Buy
2017-06-05 Eingeleitet ROTH Capital Buy
2017-03-27 Eingeleitet Laidlaw Buy
2017-02-06 Eingeleitet Rodman & Renshaw Buy
2016-03-07 Herabstufung Maxim Group Buy → Hold
2015-12-14 Bestätigt Maxim Group Buy
2015-04-30 Fortgesetzt Maxim Group Buy
2013-03-06 Eingeleitet Ascendiant Capital Markets Strong Buy
2008-01-03 Eingeleitet Dawson James Speculative Buy
Alle ansehen

Novabay Pharmaceuticals Inc Aktie (NBY) Neueste Nachrichten

pulisher
May 20, 2025

StockNews.com Begins Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World

May 20, 2025
pulisher
May 10, 2025

NovaBay fails to gain shareholder approval for dissolution - MSN

May 10, 2025
pulisher
Apr 26, 2025

NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by Analysts at StockNews.com - Defense World

Apr 26, 2025
pulisher
Apr 25, 2025

CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga

Apr 25, 2025
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 22, 2025

NovaBay Pharmaceuticals approves liquidation plan By Investing.com - Investing.com Canada

Apr 22, 2025
pulisher
Apr 22, 2025

NovaBay Pharmaceuticals approves liquidation plan - Investing.com

Apr 22, 2025
pulisher
Apr 16, 2025

Poplar Point Capital Partners acquires $39,503 in NovaBay shares - Investing.com Australia

Apr 16, 2025
pulisher
Apr 16, 2025

Poplar Point Capital Partners increases stake in NovaBay Pharmaceuticals By Investing.com - Investing.com South Africa

Apr 16, 2025
pulisher
Apr 16, 2025

Poplar Point Capital increases stake in NovaBay Pharmaceuticals - Investing.com Australia

Apr 16, 2025
pulisher
Apr 15, 2025

Massive Stock Acquisition: Poplar Point Capital Partners Bets Big on NovaBay Pharma! - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Poplar Point Capital Partners acquires $29,857 in NovaBay shares - Investing.com Australia

Apr 15, 2025
pulisher
Apr 15, 2025

Poplar Point Capital increases stake in NovaBay Pharmaceuticals By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Poplar Point Capital Partners acquires $39,503 in NovaBay shares By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Poplar Point Capital Partners acquires $29,857 in NovaBay shares By Investing.com - Investing.com Canada

Apr 15, 2025
pulisher
Apr 15, 2025

Novabay Pharmaceuticals sees $15,966 in recent stock acquisitions - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Novabay Pharmaceuticals sees $15,966 in recent stock acquisitions By Investing.com - Investing.com UK

Apr 15, 2025
pulisher
Apr 15, 2025

NovaBay Pharmaceuticals sees $67,700 stock acquisition by Poplar Point Capital - Investing.com India

Apr 15, 2025
pulisher
Apr 02, 2025

NovaBay Pharmaceuticals Inc. (NBY) reports earnings - qz.com

Apr 02, 2025
pulisher
Apr 01, 2025

NovaBay Pharmaceuticals Delays Yearly Report Filing - TipRanks

Apr 01, 2025
pulisher
Mar 27, 2025

Revolutionizing Healing: Trends in the Advanced Wound Care Market with NovaBay, Healthy.io - openPR.com

Mar 27, 2025
pulisher
Mar 24, 2025

Blepharitis Treatment Market Future Business Opportunities - openPR.com

Mar 24, 2025
pulisher
Mar 18, 2025

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Sees Significant Decrease in Short Interest - Defense World

Mar 18, 2025
pulisher
Mar 18, 2025

NovaBay Pharmaceuticals (NBY) Projected to Post Quarterly Earnings on Tuesday - Defense World

Mar 18, 2025
pulisher
Mar 12, 2025

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Share Price Passes Above 50-Day Moving Average – Time to Sell? - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

NovaBay reaches settlements over disputed warrants By Investing.com - Investing.com Australia

Mar 12, 2025
pulisher
Mar 11, 2025

NovaBay reaches settlements over disputed warrants - Investing.com India

Mar 11, 2025
pulisher
Mar 08, 2025

NovaBay Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 07, 2025

Novabay Pharmaceuticals Engages Financial Advisor Should Stockholders Fail To Approve Dissolution Proposal - Marketscreener.com

Mar 07, 2025
pulisher
Mar 07, 2025

NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders - Business Wire

Mar 07, 2025
pulisher
Mar 06, 2025

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Update - Defense World

Mar 06, 2025
pulisher
Mar 01, 2025

StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY) - Defense World

Mar 01, 2025
pulisher
Feb 27, 2025

Investor Network: NovaBay Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

NovaBay's Avenova Highlighted in National Dry Eye Awareness Month - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 21, 2025

NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com - Defense World

Feb 21, 2025
pulisher
Feb 17, 2025

NovaBay extends CEO's contract through 2025 - MSN

Feb 17, 2025
pulisher
Feb 08, 2025

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell? - Armenian Reporter

Feb 08, 2025
pulisher
Feb 04, 2025

NovaBay fails to gain shareholder approval for dissolution By Investing.com - Investing.com Canada

Feb 04, 2025

Finanzdaten der Novabay Pharmaceuticals Inc-Aktie (NBY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Novabay Pharmaceuticals Inc-Aktie (NBY) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
POPLAR POINT CAPITAL PARTNERS
10% Owner
Apr 04 '25
Buy
0.52
4,538
2,367
1,020,000
POPLAR POINT CAPITAL PARTNERS
10% Owner
Apr 02 '25
Buy
0.58
917
532
992,486
POPLAR POINT CAPITAL PARTNERS
10% Owner
Apr 08 '25
Buy
0.47
300
140
1,020,300
POPLAR POINT CAPITAL PARTNERS
10% Owner
Mar 28 '25
Buy
0.61
49,400
30,253
950,000
POPLAR POINT CAPITAL PARTNERS
10% Owner
Mar 31 '25
Buy
0.59
21,654
12,776
971,654
POPLAR POINT CAPITAL PARTNERS
10% Owner
Mar 27 '25
Buy
0.61
19,104
11,745
900,600
POPLAR POINT CAPITAL PARTNERS
10% Owner
Apr 01 '25
Buy
0.58
19,915
11,650
991,569
POPLAR POINT CAPITAL PARTNERS
10% Owner
Mar 26 '25
Buy
0.61
13,292
8,095
881,496
POPLAR POINT CAPITAL PARTNERS
10% Owner
Mar 25 '25
Buy
0.61
22,635
13,807
868,204
POPLAR POINT CAPITAL PARTNERS
10% Owner
Mar 18 '25
Buy
0.63
14,000
8,820
832,277
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):